Vaishali Pharma

{
  "main_header": {
    "sid": 1002804,
    "name": "Vaishali Pharma",
    "stock_name": "Vaishali Pharma",
    "full_name": "Vaishali Pharma Ltd",
    "name_url": "stocks-analysis/vaishali-pharma",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "7.91",
    "chg": 0.04,
    "chgp": "0.51%",
    "dir": 1,
    "prev_price": "7.87",
    "mcapval": "103.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "VAISHALI",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE972X01022",
    "curr_date": "Feb 06",
    "curr_time": "",
    "bse_nse_vol": 43857,
    "exc_status": "Active",
    "traded_date": "Feb 06, 2026",
    "traded_date_str": "2026 02 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vaishali-pharma-1002804-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Vaishali Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vaishali-pharma-ltd-is-rated-strong-sell-3809324",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/VaishaliPharmaL_mojoScore_3809324.png",
        "date": "2026-01-29 10:10:29",
        "description": "Vaishali Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 Feb 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 29 January 2026, providing investors with the latest perspective on its performance and prospects."
      },
      {
        "title": "Vaishali Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vaishali-pharma-ltd-is-rated-strong-sell-3783147",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/VaishaliPharmaL_mojoScore_3783147.png",
        "date": "2026-01-06 10:10:10",
        "description": "Vaishali Pharma Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 06 February 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 January 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Vaishali Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vaishali-pharma-ltd-is-rated-strong-sell-3769793",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/VaishaliPharmaL_mojoScore_3769793.png",
        "date": "2025-12-25 15:12:28",
        "description": "Vaishali Pharma Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 06 Feb 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Vaishali Pharma Sees Revision in Market Assessment Amid Declining Performance",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vaishali-pharma-downgraded-to-strong-sell-amid-deteriorating-fundamentals-3749888",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/VaishaliPharma_mojoScore_3749888.png",
        "date": "2025-12-06 10:10:14",
        "description": "Vaishali Pharma has experienced a revision in its market evaluation, reflecting a more cautious outlook from analysts. This shift comes amid ongoing challenges in the company’s financial and technical indicators, alongside valuation concerns, signalling increased risk for investors in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Why is Vaishali Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-vaishali-pharma-fallingrising-3749661",
        "imagepath": "",
        "date": "2025-12-06 01:40:27",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Vaishali Pharma’s share price decline on 05-Dec reflects broader challenges the company faces. The stock is trading close to its 52-week low, just 2.02% above ₹8.25, signalling sustained pressure on investor confidence. On the day, the stock underperformed its sector by 2.34%, and it remains below all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical weakness suggests a lack of short- and long-term buying momentum.</p>\n<p>Investor participation has increased, with delivery volumes rising by nearly 70% on 04-Dec compared to the five-day average, indicating heightened trading activity. However, this has not translated into price support, as the stock continues to slide.</p>\n<div class=..."
      },
      {
        "title": "How has been the historical performance of Vaishali Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-vaishali-pharma-3709127",
        "imagepath": "",
        "date": "2025-11-17 23:20:33",
        "description": "Answer:\nThe historical performance of Vaishali Pharma shows significant fluctuations in its financial metrics over the years.\n\nBreakdown:\nVaishali Pharma's net sales have shown a steady increase from INR 52.31 crore in March 2021 to INR 99.03 crore in March 2025, with a notable jump from INR 69.66 crore in March 2023 to INR 86.28 crore in March 2024. However, the total operating income peaked at INR 11.35 crore in March 2023 but dropped to INR 3.31 crore by March 2025. The operating profit margin, which was as high as 13.09% in March 2023, fell sharply to 0.1% in March 2025. Profit before tax also declined significantly from INR 8.85 crore in March 2023 to INR 1.23 crore in March 2025, while profit after tax decreased from INR 6.60 crore to INR 0.82 crore in the same period. The company's total assets increased from INR 66.08 crore in March 2020 to INR 109.66 crore in March 2025, reflecting growth in shareh..."
      },
      {
        "title": "How has been the historical performance of Vaishali Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-vaishali-pharma-3703933",
        "imagepath": "",
        "date": "2025-11-15 00:19:10",
        "description": "Answer:\nThe historical performance of Vaishali Pharma shows significant fluctuations in key financial metrics over the years.\n\nBreakdown:\nVaishali Pharma's net sales have shown a steady increase from INR 52.31 crore in March 2021 to INR 99.03 crore in March 2025, with a notable jump from INR 69.66 crore in March 2023 to INR 86.28 crore in March 2024. However, the total operating income peaked at INR 11.35 crore in March 2023 but dropped to INR 3.31 crore by March 2025. The operating profit margin, which was at 13.09% in March 2023, fell drastically to 0.1% in March 2025. Profit before tax also reflected this trend, decreasing from INR 8.85 crore in March 2023 to INR 1.23 crore in March 2025. Profit after tax followed a similar pattern, declining from INR 6.60 crore in March 2023 to INR 0.82 crore in March 2025. The company's total liabilities increased from INR 66.08 crore in March 2020 to INR 109.66 crore ..."
      }
    ],
    "total": 63,
    "sid": "1002804",
    "stock_news_url": "https://www.marketsmojo.com/news/vaishali-pharma-1002804"
  },
  "announcements": [
    {
      "details": "Vaishali Pharma Limited has informed the Exchange regarding Resignation of Ms Khushboo M Panchal as Company Secretary & Compliance Officer of the company w.e.f. October 31, 2019.",
      "source": "NSE",
      "caption": "Vaishali Pharma Limited - Resignation",
      "datetime": "01-Nov-2019"
    },
    {
      "details": "Vaishali Pharma Limited has informed the Exchange regarding allotment of 3954828 securities pursuant to Bonus at its meeting held on October 19, 2019",
      "source": "NSE",
      "caption": "Vaishali Pharma Limited - Allotment of Securities",
      "datetime": "22-Oct-2019"
    },
    {
      "details": "Vaishali Pharma Limited has informed the Exchange that the Company has fixed Record Date as October 18, 2019 for the purpose of Allotment of Bonus Shares .(Revised)",
      "source": "NSE",
      "caption": "Vaishali Pharma Limited - Record Date",
      "datetime": "16-Oct-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Vaishali Pharma Ltd has announced <strong>2:10</strong> stock split, ex-date: 15 Oct 24",
          "dt": "2024-10-15",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Vaishali Pharma Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 15 Oct 24",
          "dt": "2024-10-15",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Vaishali Pharma Ltd is Rated Strong Sell

2026-01-29 10:10:29

Vaishali Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 Feb 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 29 January 2026, providing investors with the latest perspective on its performance and prospects.

Read full news article

Vaishali Pharma Ltd is Rated Strong Sell

2026-01-06 10:10:10

Vaishali Pharma Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 06 February 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 January 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Vaishali Pharma Ltd is Rated Strong Sell

2025-12-25 15:12:28

Vaishali Pharma Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 06 Feb 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into its performance and outlook.

Read full news article

Vaishali Pharma Sees Revision in Market Assessment Amid Declining Performance

2025-12-06 10:10:14

Vaishali Pharma has experienced a revision in its market evaluation, reflecting a more cautious outlook from analysts. This shift comes amid ongoing challenges in the company’s financial and technical indicators, alongside valuation concerns, signalling increased risk for investors in the Pharmaceuticals & Biotechnology sector.

Read full news article

Why is Vaishali Pharma falling/rising?

2025-12-06 01:40:27

Recent Price Movement and Market Context

Vaishali Pharma’s share price decline on 05-Dec reflects broader challenges the company faces. The stock is trading close to its 52-week low, just 2.02% above ₹8.25, signalling sustained pressure on investor confidence. On the day, the stock underperformed its sector by 2.34%, and it remains below all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical weakness suggests a lack of short- and long-term buying momentum.

Investor participation has increased, with delivery volumes rising by nearly 70% on 04-Dec compared to the five-day average, indicating heightened trading activity. However, this has not translated into price support, as the stock continues to slide.

Read full news article

How has been the historical performance of Vaishali Pharma?

2025-11-17 23:20:33

Answer: The historical performance of Vaishali Pharma shows significant fluctuations in its financial metrics over the years. Breakdown: Vaishali Pharma's net sales have shown a steady increase from INR 52.31 crore in March 2021 to INR 99.03 crore in March 2025, with a notable jump from INR 69.66 crore in March 2023 to INR 86.28 crore in March 2024. However, the total operating income peaked at INR 11.35 crore in March 2023 but dropped to INR 3.31 crore by March 2025. The operating profit margin, which was as high as 13.09% in March 2023, fell sharply to 0.1% in March 2025. Profit before tax also declined significantly from INR 8.85 crore in March 2023 to INR 1.23 crore in March 2025, while profit after tax decreased from INR 6.60 crore to INR 0.82 crore in the same period. The company's total assets increased from INR 66.08 crore in March 2020 to INR 109.66 crore in March 2025, reflecting growth in shareh...

Read full news article

How has been the historical performance of Vaishali Pharma?

2025-11-15 00:19:10

Answer: The historical performance of Vaishali Pharma shows significant fluctuations in key financial metrics over the years. Breakdown: Vaishali Pharma's net sales have shown a steady increase from INR 52.31 crore in March 2021 to INR 99.03 crore in March 2025, with a notable jump from INR 69.66 crore in March 2023 to INR 86.28 crore in March 2024. However, the total operating income peaked at INR 11.35 crore in March 2023 but dropped to INR 3.31 crore by March 2025. The operating profit margin, which was at 13.09% in March 2023, fell drastically to 0.1% in March 2025. Profit before tax also reflected this trend, decreasing from INR 8.85 crore in March 2023 to INR 1.23 crore in March 2025. Profit after tax followed a similar pattern, declining from INR 6.60 crore in March 2023 to INR 0.82 crore in March 2025. The company's total liabilities increased from INR 66.08 crore in March 2020 to INR 109.66 crore ...

Read full news article

View All News